Cargando…

Immunotherapy: Shifting the Balance of Cell-Mediated Immunity and Suppression in Human Prostate Cancer

Active immunotherapy is dependent on the ability of the immune system to recognize and respond to tumors. Despite overwhelming evidence to support a cell-mediated immune response to prostate cancer, it is insufficient to eradicate the disease. This is likely due to a high level of suppression at the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tucker, Jo A., Jochems, Caroline, Gulley, James L., Schlom, Jeffrey, Tsang, Kwong Y.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2012
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3712722/ https://www.ncbi.nlm.nih.gov/pubmed/24213509 http://dx.doi.org/10.3390/cancers4041333

Ejemplares similares

Identification and characterization of agonist epitopes of the MUC1-C oncoprotein
por: Jochems, Caroline, et al.
Publicado: (2013)

Generation of human T cells directed against an agonist epitope of Brachyury, a transcription factor involved in human tumor cell epithelial to mesenchymal transition (EMT)
por: Boyerinas, Benjamin, et al.
Publicado: (2013)

Evaluation of immune cell subsets of cancer patients treated with Avelumab, a fully human IgG1 anti-PD-L1 MAb capable of mediating ADCC of human tumor cells
por: Lepone, Lauren, et al.
Publicado: (2015)

The Consequence of Immune Suppressive Cells in the Use of Therapeutic Cancer Vaccines and Their Importance in Immune Monitoring
por: Vergati, Matteo, et al.
Publicado: (2011)

Investigation of antibody dependent cellular cytotoxicity as a mechanism of action for a novel anti-PD-L1 monoclonal antibody
por: Boyerinas, Benjamin, et al.
Publicado: (2014)

The role of soluble CD40L in immunosuppression
por: Schlom, Jeffrey, et al.
Publicado: (2013)

Digital immunohistochemistry analysis of intratumoral immune infiltrates in prostate cancer patients treated with intraprostatic/systemic PSA-TRICOM vaccine
por: Farsaci, Benedetto, et al.
Publicado: (2013)

Long-Term Survival and PSA Control with Radiation and Immunotherapy for Node Positive Prostate Cancer
por: Kamrava, M., et al.
Publicado: (2009)

Immune correlates of clinical parameters in patients with HPV-associated malignancies treated with bintrafusp alfa
por: Tsai, Yo-Ting, et al.
Publicado: (2022)

Impact of androgen deprivation therapy on the thymus and the production of naïve T-cells
por: Madan, Ravi A, et al.
Publicado: (2013)

Dual targeting of TGF-β and PD-L1 via a bifunctional anti-PD-L1/TGF-βRII agent: status of preclinical and clinical advances
por: Lind, Hanne, et al.
Publicado: (2020)

ABO blood type correlates with survival on prostate cancer vaccine therapy
por: Muthana, Saddam M., et al.
Publicado: (2015)

Improving the Odds in Advanced Breast Cancer With Combination Immunotherapy: Stepwise Addition of Vaccine, Immune Checkpoint Inhibitor, Chemotherapy, and HDAC Inhibitor in Advanced Stage Breast Cancer
por: Gatti-Mays, Margaret E., et al.
Publicado: (2021)

Developing immunotherapy strategies in the treatment of prostate cancer
por: Gulley, James L., et al.
Publicado: (2016)

Analyses of functions of an anti-PD-L1/TGFβR2 bispecific fusion protein (M7824)
por: Jochems, Caroline, et al.
Publicado: (2017)

Phase I study of a multitargeted recombinant Ad5 PSA/MUC-1/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC)
por: Bilusic, Marijo, et al.
Publicado: (2021)

Combination Therapies for HPV-Associated Malignancies
por: Smalley Rumfiled, Claire, et al.
Publicado: (2020)

Perspectives on the clinical development of immunotherapy in prostate cancer
por: Cordes, Lisa M, et al.
Publicado: (2018)

Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody
por: Donahue, Renee N., et al.
Publicado: (2017)

Beyond the Immune Suppression: The Immunotherapy in Prostate Cancer
por: Silvestri, Ida, et al.
Publicado: (2015)

The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cells
por: Jochems, Caroline, et al.
Publicado: (2016)

Immunotherapy and therapeutic vaccines in prostate cancer: an update on current strategies and clinical implications
por: Singh, B Harpreet, et al.
Publicado: (2014)

Effects of conventional therapeutic interventions on the number and function of regulatory T cells
por: Roselli, Mario, et al.
Publicado: (2013)

The generation and analysis of a novel combination of recombinant adenovirus vaccines targeting three tumor antigens as an immunotherapeutic
por: Tsang, Kwong Y, et al.
Publicado: (2015)

The Use of a Humanized NSG-β2m(−/−) Model for Investigation of Immune and Anti-tumor Effects Mediated by the Bifunctional Immunotherapeutic Bintrafusp Alfa
por: Morillon, Y. Maurice, et al.
Publicado: (2020)

Immunologic Monitoring of Cellular Immune Responses in Cancer Vaccine Therapy
por: Whiteside, Theresa L., et al.
Publicado: (2011)

Treatment with the IDO inhibitor INCB024360 increased lysis of human tumor cell targets by peptide-specific CTL
por: Jochems, Caroline, et al.
Publicado: (2015)

Immunomodulation to enhance the efficacy of an HPV therapeutic vaccine
por: Smalley Rumfield, Claire, et al.
Publicado: (2020)

Enhanced killing of chordoma cells by antibody-dependent cell-mediated cytotoxicity employing the novel anti-PD-L1 antibody avelumab
por: Fujii, Rika, et al.
Publicado: (2016)

Samarium-153-EDTMP (Quadramet(®)) with or without vaccine in metastatic castration-resistant prostate cancer: A randomized Phase 2 trial
por: Heery, Christopher R., et al.
Publicado: (2016)

Inhibitors of histone deacetylase 1 reverse the immune evasion phenotype to enhance T-cell mediated lysis of prostate and breast carcinoma cells
por: Gameiro, Sofia R., et al.
Publicado: (2016)

Early changes in immune cell subsets with corticosteroids in patients with solid tumors: implications for COVID-19 management
por: Marté, Jennifer L, et al.
Publicado: (2020)

Therapeutic Vaccines for HPV-Associated Malignancies
por: Smalley Rumfield, Claire, et al.
Publicado: (2020)

Strategies for Cancer Vaccine Development
por: Vergati, Matteo, et al.
Publicado: (2010)

Epigenetic priming of both tumor and NK cells augments antibody-dependent cellular cytotoxicity elicited by the anti-PD-L1 antibody avelumab against multiple carcinoma cell types
por: Hicks, Kristin C., et al.
Publicado: (2018)

Western diet shifts immune cell balance
por: Bergey, Christina M
Publicado: (2021)

Flow-cytometry phenotypic assessment of immune cell subsets reflecting function for the identification of breast cancer patients receiving vaccine plus docetaxel with longer progression-free survival
por: Grenga, Italia, et al.
Publicado: (2013)

An NK cell line (haNK) expressing high levels of granzyme and engineered to express the high affinity CD16 allele
por: Jochems, Caroline, et al.
Publicado: (2016)

Effect of age and cancer on peripheral immune cell subsets and their PD-1 and PD-L1 expression
por: Grenga, Italia, et al.
Publicado: (2015)

Preclinical study of a novel therapeutic vaccine for recurrent respiratory papillomatosis
por: Lee, Maxwell Y., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_7iqg96hb85mr356hel4tikfmq4